Co­manche lines up tri­al for preeclamp­sia siR­NA with Mod­er­na, Med­i­cines Com­pa­ny vets and GV back­ing

A new siR­NA biotech from Mod­er­na and Med­i­cines Com­pa­ny vet­er­ans is near­ing the clin­ic as it looks to ad­dress ris­ing ma­ter­nal health risks and re­duce a life-threat­en­ing com­pli­ca­tion in preg­nan­cies that im­pacts mil­lions of women like Allyson Fe­lix, Amer­i­ca’s most-dec­o­rat­ed track Olympian.

The start­up, Co­manche Bio­phar­ma, has been op­er­at­ing most­ly in stealth mode un­til this point, and is de­vel­op­ing a one-time ther­a­py that it hopes will work for about 90% of preeclamp­sia cas­es, said chief med­ical of­fi­cer Al­li­son Au­gust, a for­mer VP of clin­i­cal de­vel­op­ment for in­fec­tious dis­eases at Mod­er­na. Fe­lix was al­so re­cent­ly named a board mem­ber.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN